HelmholtzZentrum munich

Connecting genetic risk to disease endpoints through the human blood plasma proteome


Proteome annotation
Locus annotations

Locus 207

Top associations per target

Target cis/​trans Study SNP SNP location Maj/​min allele MAF N βinv seinv Pinv fclog Plog Praw
RET cis Discovery rs2505535 10:43,593,043 G/A 0.27 993 -0.431 0.047 2.8×10-19 -1.100 9.5×10-15 1.2×10-8
RET cis Replication rs7092603 10:43,552,931 A/G 0.28 337 -0.368 0.072 5.5×10-7 -1.160 5.6×10-7 5.8×10-5


Regional association plots

Proto-oncogene tyrosine-protein kinase receptor Ret (RET)


Boxplots and histograms for top associations

Proto-oncogene tyrosine-protein kinase receptor Ret (RET)

inverse-normalized probe levels log2 transformed probe levels raw probe levels
Discovery study
Replication study

Proto-oncogene tyrosine-protein kinase receptor Ret (RET)

Target (abbrv.) RET
Target (full name) Proto-oncogene tyrosine-protein kinase receptor Ret
Somalogic ID (Sequence ID) SL010378 (3220-40_2)
Entrez Gene Symbol RET
UniProt ID P07949
UniProt Comment
  • Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration.
Targeted by drugs (based on IPA annotation)
  • sunitinib
  • motesanib
  • cabozantinib
  • regorafenib
  • ponatinib
  • bortezomib/sorafenib
  • dexamethasone/lenalidomide/sorafenib
  • bevacizumab/sorafenib
  • imatinib/sirolimus
  • cabozantinib/erlotinib
  • imatinib/nilotinib/pegintron
  • imatinib
  • sorafenib
  • vandetanib
Biomarker applications (based on IPA annotation)
  • efficacy
  • response to therapy
Wiki Pathways
  • SIDS Susceptibility Pathways
Pathway Interaction Database
  • Posttranslational regulation of adherens junction stability and dissassembly
  • Signaling events regulated by Ret tyrosine kinase
Pathway Studio
  • GDNF → HSF1 signaling
  • GFs/TNF → ion channels
  • Regulation of calcium flux

All locus annotations are based on the sentinel SNP (rs2505535) and 41 proxy variant(s) that is/are in linkage disequilibrium r2 ≥ 0.8. Linkage disequilibrium is based on data from the 1000 Genomes Project, phase 3 version 5, European population and was retrieved using SNiPA's Block Annotation feature.
Download the detailed results of SNiPA's block annotation (PDF)

Linked genes

Genes hit or close-by
  • RET ret proto-oncogene
Potentially regulated genes
eQTL genes


Results from other genome-wide association studies

Trait P Study Source
cg06632098 (chr10:43605930) 3.3×10-310 10.1101/033084 (DOI) BIOS QTL cis-meQTLs
Hirschsprung<92>s disease 3.8×10-17 19196962 (PMID) GRASP2 nonQTL
cg06559368 (chr10:43573295) 4.6×10-6 10.1101/033084 (DOI) BIOS QTL cis-meQTLs
cg14325778 (chr10:43375460) 5.6×10-6 10.1101/033084 (DOI) BIOS QTL cis-meQTLs
cg04322572 (chr10:43447642) 7.2×10-6 10.1101/033084 (DOI) BIOS QTL cis-meQTLs
Time-to-recurrence during lithium treatment for bipolar disorder 4.8×10-4 19448189 (PMID) GRASP2 nonQTL